### INFLAMMATION AND INFLAMMATORY BOWEL DISEASE

# Mucosal protection against sulphide: importance of the enzyme rhodanese

#### R Picton, M C Eggo, G A Merrill, M J S Langman, S Singh

.....

Gut 2002;50:201-205

**Background:** Hydrogen sulphide  $(H_2S)$  is a potent toxin normally present in the colonic lumen which may play a role in ulcerative colitis (UC). Two enzymes, thiol methyltransferase (TMT) and rhodanese (RHOD), are thought to be responsible for sulphide removal but supportive evidence is lacking.

**Aims:** To determine the distribution of TMT and RHOD in different sites throughout the gastrointestinal tract and their efficacy as detoxifiers of  $H_2S$ .

**Methods:** Enzyme activities were measured in normal tissue resected from patients with cancer. TMT and RHOD activities were determined using their conventional substrates, 2-mercaptoethanol and sodium thiosulphate, respectively. For measurement of H<sub>2</sub>S metabolism, sodium sulphide was used in the absence of dithiothreitol. Thiopurine methyltransferase (TPMT), which in common with TMT methylates sulphydryl groups but is not thought to act on H<sub>2</sub>S, was also examined.

**Results:** TMT, RHOD, and TPMT activities using their conventional substrates were found throughout the gastrointestinal tract with highest activity in the colonic mucosa. When H<sub>2</sub>S was given as substrate, no reaction product was found with TMT or TPMT but RHOD was extremely active (Km 8.8 mM, Vmax 14.6 nmol/mg/min). Incubation of colonic homogenates with a specific RHOD antibody prevented the metabolism of H<sub>2</sub>S, indicating that RHOD is responsible for detoxifying H<sub>2</sub>S. A purified preparation of RHOD also detoxified H<sub>2</sub>S.

**Conclusions:** RHOD, located in the submucosa and crypts of the colon, is the principal enzyme involved in  $H_2S$  detoxication. TMT does not participate in the detoxication of  $H_2S$ .

The concentration of hydrogen sulphide (H<sub>2</sub>S) in human faeces, varying between 1.0 and 2.4 mmol/kg, is well within the known toxic range.<sup>1</sup> H<sub>2</sub>S is released in the colonic lumen by anaerobic sulphate reducing bacteria from sulphate, originating from dietary sulphur containing preservatives, mucin sulphate, and by amino acid fermenting bacteria from sulphur containing amino acids.<sup>1</sup> H<sub>2</sub>S disrupts cellular energy synthesis by complexing with enzymes responsible for oxidative phosphorylation,<sup>2</sup> and is known to inhibit butyrate metabolism,<sup>3</sup> a more important source of energy than glucose in the colonic mucosa.<sup>4</sup>

The possible importance of  $H_2S$  as an aetiological agent or as a cofactor in the genesis or maintenance of ulcerative colitis (UC) is suggested by evidence that counts of sulphate reducing bacteria are raised in the faeces of patients with active UC,<sup>5</sup> that  $H_2S$  concentrations are also increased,<sup>6</sup> and that butyrate oxidation is inhibited.<sup>3</sup> The toxic effects of  $H_2S$  and its mercapto derivatives would be expected to be mitigated by effective removal mechanisms. The enzymes thiol methyltransferase (TMT) and rhodanese (RHOD) have both been suggested to be capable of removing  $H_2S$  and these mercapto derivatives, but supportive evidence is lacking.<sup>7 &</sup> If either enzyme is important in  $H_2S$  detoxification, it would be expected to be detectable in high concentrations in the colonic mucosa, and the ability to remove  $H_2S$  should easily be demonstrable.

We have therefore examined the activity of both enzymes throughout the gastrointestinal tract using synthetic substrates. We have also examined the distribution of another enzyme active against sulphydryl groups, thiopurine methyl-transferase (TPMT), but which has no recognised action on  $H_2S$ .<sup>9</sup> We have determined the relative importance of the enzymes in the detoxication of  $H_2S$ .

#### MATERIALS AND METHODS

#### **Tissue preparation**

A total of 73 samples, obtained at surgery during routine operative procedures from the oesophagus to the rectum from 40 patients (24 male, 16 female) with a mean age of 56 years (range 28–91), were analysed. Three of 11 patients who provided upper gastrointestinal tract tissue samples (oesophagus and stomach) were taking omeprazole. Two of the nine patients who provided lower gastrointestinal tract tissue samples (small intestine, right colon, left colon, and rectum) were taking prednisolone, and one of the nine was taking sulphasalazine. Normal tissue was resected from patients with cancer at a site distant from the primary carcinoma. Samples from both the muscularis propria and the mucosa (comprising both the submucosa and crypts) were analysed. The muscularis propria was stripped from the mucosal layers by blunt dissection, frozen in liquid nitrogen, and stored at  $-70^{\circ}$ C.

#### Crypt preparation

Mucosal epithelial crypts were prepared by scraping a scalpel blade along the mucosal surface to separate the mucosa from the submucosa. Intact crypts were obtained by digestion in 0.1% collagenase (type 1, Worthington) for one hour. Cells were cultured in suspension for 24 hours in Dulbecco's modified Eagle's medium before harvesting by centrifugation at 1000 *g* for five minutes in a bench top centrifuge.

**Abbreviations:** H<sub>2</sub>S, hydrogen sulphide; DTT, dithiothreitol; Vmax, maximal velocity; MST, mercaptopyruvate sulphur transferase; Km, Michaelis-Menten constant; RHOD, rhodanese; TMT, thiol methyltransferase; TPMT, thiopurine methyltransferase; UC, ulcerative colitis.

Correspondence to:

See end of article for

authors' affiliations

Dr S Singh, Good Hope Hospital, Sutton Coldfield, Birmingham B75 7RR, UK; s.singh@bham.ac.uk

Accepted for publication 29 March 2001



Figure 1 Distribution of (A) thiol methyltransferase (TMT), (B) rhodanese (RHOD), and (C) thiopurine methyltransferase (TPMT) throughout the gastrointestinal tract for the mucosa and the muscularis propria. O, oesophagus; ST, stomach; SI, small intestine; RC, right colon; LC, left colon; R, rectum.

#### TMT assay

The activity of TMT was measured using a method based on that of Pacifici and colleagues<sup>9</sup> and Weinshilboum and colleagues<sup>10</sup> with 2-mercaptoethanol as substrate. Tissue homogenate was incubated with 100 mM (low affinity enzyme reaction) or 30  $\mu$ M (high affinity enzyme reaction) 2-mercaptoethanol and 100  $\mu$ M <sup>3</sup>H-S-adenosyl methionine (500 mCi/mmol; Amersham, UK) in 0.1 M potassium phosphate buffer with 1 mM EDTA and 0.5% Triton-X-100 (pH 7.9) at 37°C for 10 minutes in a final volume of 25  $\mu$ l. Reactions were terminated on ice by the addition of an equal volume of 1 M hydrochloric acid. Radiolabelled product was extracted into 10 volumes of toluene. Each sample was assayed in triplicate together with a heated enzyme (100°C, 10 minutes) and a no enzyme control.

#### **RHOD** assay

RHOD activity was measured using sodium thiosulphate as substrate, as described by Aminlari and Gilanpour,<sup>11</sup> based on the work of Sorbo.<sup>12</sup> Tissue homogenate was incubated with 50

mM sodium thiosulphate, 50 mM potassium cyanide, and 40 mM sodium glycine buffer (pH 9.2) at 20°C for 10 minutes in a final volume of 200  $\mu$ l. Reactions were terminated on ice by the addition of 37% formaldehyde. The reaction product, thiocyanate, forms a red precipitate on mixing with an equal volume of 0.025 M ferric nitrate and was detected at 460 nm with a Pharmacia LKB-Ultrospec III spectrophotometer. Each sample was assayed in triplicate together with a formaldehyde inactivated enzyme control.

#### **TPMT** assay

The activity of TPMT was measured using 6-mercaptopurine as substrate, as described by Pacifici and colleagues<sup>9</sup> and Weinshilboum and colleagues.<sup>13</sup> Tissue homogenate was incubated with 4 mM 6-mercaptopurine added in 2.5 µl dimethyl sulphoxide together with 50 µM allopurinol, 5 mM dithiothreitol, and 25 µM <sup>3</sup>H-S-adenosyl methionine (500 mCi/mmol; Amersham) in 0.1 M potassium phosphate buffer containing 0.5% Triton-X-100 (pH 6.7) at 37°C for 60 minutes in a total volume of 25 µl. Reactions were terminated on ice by addition

	TMT activity (pmol/mg/min)	RHOD activity (nmol/mg/min)	TPMT activity (pmol/mg/min)
Oesophagus	17.6 (5.4) (n=6)	46.7 (18.1) (n=6)	66.8 (12.2) (n=6)
Stomach	51.5 (11.9) (n=9)	127.6 (26.1) (n=9)	189.2 (37.9) (n=9)
Small intestine	91.7 (16.7) (n=9)	157.6 (26.0) (n=9)	156.4 (35.8) (n=9)
Right colon	114.4 (15.9) (n=8)	292.4 (80.9) (n=6)	182.5 (34.2) (n=8)
Left colon	82.4 (16.8) (n=11)	245.6 (38.9) (n=10)	209.5 (31.5) (n=11)
Rectum	72.4 (10.7) (n=7)	253.9 (39.4) (n=7)	223.3 (21.1) (n=7)

 Table 1
 Mucosal thiol methyltransferase (TMT), rhodanese (RHOD), and thiopurine methyltransferase (TPMT) activity at each site throughout the gastrointestinal tract

of an equal volume of 0.5 M sodium borate, pH 9.5. Radiolabelled product was extracted into 10 volumes of 10% isoamyl alcohol in toluene. Each sample was assayed in triplicate with controls of heated enzyme (100°C, 10 minutes) and no enzyme.

#### Thiocyanate levels in plasma

Plasma was prepared from freshly obtained whole blood in EDTA by centrifugation at 2000 *g*. Plasma was removed from the pelleted whole cells and no haemolysis was evident. An equal volume of ferric nitrate was added to aliquots of plasma and product measured as described for the RHOD assay.

#### **Protein determination**

Protein concentration was calculated by the Bradford method<sup>14</sup> using an equal volume of tissue homogenate buffer as the control for background absorbance.

#### Immunoprecipitation of RHOD

RHOD was immunoprecipitated by overnight incubation at 4°C with a rabbit antirhodanese polyclonal antiserum<sup>15</sup> using normal rabbit serum as a control. Complexed rabbit 7 antirhodanese antibody was immunoprecipitated using formalin fixed staphylococcus protein A (Sigma, St Louis, Missouri, USA). The precipitate was removed by centrifugation. The supernatant was assayed for RHOD, TMT, and TPMT activity using the standard methods described above. Background levels of product were measured with no substrate, no enzyme, and heated enzyme controls.

#### RESULTS

#### Enzyme distribution in the gastrointestinal tract

The distribution of TMT, RHOD, and TPMT throughout the gastrointestinal tract is shown in fig 1A-C, respectively, for the mucosa and the muscularis propria. Table 1 shows the mean (SEM) data for mucosal activity of all three enzymes throughout the gastrointestinal tract. The distribution of all three enzymes was similar with activity highest in the large bowel mucosa (right colon, left colon, and rectum) and lowest in the oesophagus. TMT activity in the large bowel was similar to that in the small intestine but was significantly higher than that in the oesophagus and stomach mucosa (p=0.04, Mann Whitney U test) (fig 1A). Activity within the large bowel (right colon, left colon, and rectum) did not differ significantly. Activity of low affinity TMT was closely correlated with high affinity TMT (correlation coefficient 0.80, data not shown). Similar to TMT, RHOD mucosal activity (fig 1B) was significantly lower in the oesophagus, increasing threefold in the stomach (p=0.026, Mann Whitney U test). Activity continued to rise throughout the gastrointestinal tract and in the left colon and rectum was significantly greater than in the stomach (p=0.04, p=0.008, respectively, Mann Whitney U test) (fig 1B). TPMT activity (fig 1C) was also lower in the oesophagus compared with the stomach (p=0.017, Mann Whitney U test). Although the trend was upward towards the rectum, there was no significant difference between the small intestine or stomach and the large bowel.

Activity was approximately 50% higher in the mucosa compared with the muscularis propria (fig 1A–C), which mirrored the distribution found in the mucosa. Enzyme activity within the mucosa was further studied by assaying activity within epithelial crypt pellets. Activity of TMT in crypts was 669.9 (SEM 115.7) pmol/mg/min (n=13) compared with 89.5 (9.4) pmol/mg/min (n=26) in the large bowel mucosa, indicating that TMT activity is predominantly localised within the crypts in the mucosa. RHOD activity was similar in both preparations (190.8 (89.9) nmol/mg/min (n=13) in crypts compared with 260.3 (28.3) nmol/mg/min (n=23) in large bowel mucosa) indicating that RHOD activity is not confined to crypts. TPMT activity was 22.6 (3.5) pmol/mg/min (n=13) in crypts compared with 204.9 (17.5) pmol/mg/min (n=26) in the underlying mucosa, indicating that in contrast, TPMT activity is not localised in crypts.

Enzyme affinity constants for TMT, RHOD, and TPMT were calculated from dose-response curves using the methods of Eadie-Hoffstee and Hanes.<sup>16</sup> The calculated Michaelis-Menten constant (Km) for TMT (low affinity) using 2-mercaptoethanol as substrate was 5.2 mM and the high affinity Km was 0.01 mM. The Km for RHOD using thiosulphate as substrate was 1.1 mM and that for TPMT using 6-mercaptopurine as substrate 0.26 mM.

#### TMT action on H<sub>2</sub>S

In an earlier report examining the effect of TMT on H<sub>2</sub>S, dithiothreitol (DTT) was included as a reducing agent<sup>7</sup> and an apparent Km for H<sub>2</sub>S of 8 mM was found. We found however that DTT is itself a substrate for TMT, as shown in fig 2, with a Km of 11.5 mM and a maximal velocity (Vmax) of 527.4 pmol/mg/min. Incubation of enzyme with a wide range of H<sub>2</sub>S concentrations (nM to M) in the presence of 0.2 mM DTT had no additive effect, confirming that DTT, and not H<sub>2</sub>S, is metabolised by TMT (data not shown). Experiments examining the effect of TMT on H<sub>2</sub>S were therefore performed in the absence of DTT. No enzyme activity was seen when H<sub>2</sub>S (supplied as sodium sulphide) was used as substrate (n=8) (fig 3). To check for functional enzyme activity, parallel experiments using 2-mercaptoethanol as substrate continued to show enzyme activity consistent with functioning enzyme. As no toluene extractable reaction product was formed with <sup>3</sup>H-S-adenosyl methionine, these data contradict the earlier report<sup>7</sup> and show that TMT is unable to detoxify H<sub>2</sub>S.

#### RHOD action on H<sub>2</sub>S

RHOD action on  $H_2S$  (supplied as sodium sulphide) was determined with 50 mM cyanide as cosubstrate in place of thiosulphate. High levels of enzyme activity were found, as shown in fig 3. Vmax was 14.6 nmol/mg/min, and at a physiological concentration of 1 mM activity was 6.7 nmol/mg/min. The calculated Km was 8.8 mM. At very high concentrations of  $H_2S$  (>30 mM) there was inhibition of enzyme action.

#### Thiocyanate levels in plasma

Thiocyanate levels in plasma from controls and smokers were measured at 0.19 (0.01) mM (n=42) and 0.32 (0.04) mM (n=16), respectively.



**Figure 2** Effect of thiol methyltransferase (TMT) on dithiothreitol (DTT). DTT is itself a substrate for TMT, with a Km of 11.5 mM and a maximal velocity of 527.4 pmol/mg/min.



Figure 3 Effect of rhodanese (RHOD) on hydrogen sulphide ( $H_2S$ ) (supplied as sodium sulphide). High levels of enzyme activity were found with a maximal velocity of 14.6 nmol/mg/min. The calculated Km was 8.8 mM.

## Effect of antibody to RHOD on H<sub>2</sub>S detoxification in colonic homogenates

RHOD assays in colonic homogenates and using thiosulphate or  $H_2S$  as substrate in the presence or absence of polyclonal antibody to RHOD were performed. Addition of antibody inhibited enzyme activity greatly when either thiosulphate (92% reduction) or  $H_2S$  (86% reduction) was used as substrate. No effect was seen on enzyme activity when similar volumes of normal rabbit serum were added. Polyclonal antibody to RHOD had no effect on the activity of TMT or TPMT (data not shown).

#### Action of purified bovine RHOD on H<sub>2</sub>S

Purified bovine liver RHOD (Sigma) action on  $H_2S$  was determined with 50 mM cyanide as cosubstrate, as shown in fig 4, and illustrated a similar dose-response to that produced by colonic mucosal RHOD. At concentrations of >30 mM,  $H_2S$  inhibited enzyme activity, as found in the colonic homogenate. Antibody to RHOD was also effective when used with bovine RHOD. When incubated with the antibody, purified bovine RHOD activity on  $H_2S$  was lost (100%).



**Figure 4** Effect of purified bovine liver rhodanese (RHOD) on hydrogen sulphide (H<sub>2</sub>S). A similar dose-response to that produced by colonic mucosal RHOD was illustrated.

#### DISCUSSION

We have found that the activities of all three enzymes studied were highest in the large bowel and lowest in the oesophagus, with results consistently higher in the mucosa than in the muscularis propria of the submucosa. Although the findings for TMT distribution and for the chosen control, TPMT, agree with previous results,<sup>9 17</sup> those for RHOD are new. When comparing activities in the crypts and the mucosa (comprising crypts and submucosa), total TMT activity was accounted for in the crypt cells, RHOD was in both crypts and the submucosa, whereas TPMT was principally in the submucosa.

When sodium sulphide was used as a direct source of H<sub>2</sub>S, high levels of RHOD activity were found in the presence of cyanide as cosubstrate, with a Vmax of 14.6 nmol/mg/min and a Km of 8.8 mM. In contrast, TMT (in the absence of DTT) did not remove H<sub>2</sub>S generated from sodium sulphide. This finding disagrees with the results of others<sup>7</sup> but activity noted in the past may have reflected the presence of DTT in the reaction mix as we have shown that DTT is a good substrate for TMT. That RHOD was the responsible enzyme for sulphide removal in our studies was confirmed by the loss of activity with a polyclonal antibody to RHOD. Separate experiments showed that purified bovine liver RHOD has a similar ability to detoxify H<sub>2</sub>S and that RHOD antibody also blocked enzyme activity. In vivo clearance of H<sub>2</sub>S in rat colon has recently been estimated to be 20 nmol/mg/min.<sup>18</sup> We found that in human colonic homogenates, a similar level of RHOD enzyme activity exists at physiological concentrations of H<sub>2</sub>S (1-2 mM), substantiating the claim that this enzyme may be the in vivo detoxifier of H<sub>2</sub>S.<sup>18</sup>

Levitt and colleagues<sup>18</sup> have demonstrated radiolabelled  $H_2S$  removal in rat caecal blood and have shown that the TMT transmethylation reaction is not involved, in contrast with data recently reported using 2-mercaptoethanol as substrate.<sup>19</sup> Our studies indicate that RHOD is likely to be the responsible enzyme for detoxification of  $H_2S$ . In vivo, data to date have focused on the role of RHOD as a detoxifier of cyanide and not on the role proposed here, as a detoxifier of  $H_2S$ . The source of the cyanide cosubstrate is unknown but we found that prevailing levels of thiocyanate are high in plasma (0.19 mM in non-smokers and 0.32 mM in smokers), indicating that there is an ample source of cyanide available to act as cosubstrate in the proposed reaction.

Molecular data have introduced a second closely related enzyme with a possible role in the detoxication of  $H_2S$ , namely mercaptopyruvate sulphur transferase (MST). MST has 60% homology to RHOD<sup>20</sup> and can perform the same reaction as RHOD but is thought to primarily catalyse the production of thiosulphate from mercaptopyruvate and a sulphydryl group donor. Similarly, RHOD will catalyse the formation of thiosulphate although it primarily transfers sulphydryl groups to cyanide, forming thiocyanate and sulphate.<sup>20</sup> In common with RHOD, MST is found in mitochondria but is also found in the cytosol.<sup>12</sup> The balance of expression of RHOD and MST in various tissues is not known or whether both enzymes are required for effective detoxication of H<sub>2</sub>S. Finally, our data offer an explanation for the reduced incidence of UC in smokers. Cyanide and sulphide react together to form thiocyanate under the influence of RHOD which may explain why smokers have raised levels of thiocyanate as shown here, consequent on cyanide removal from inhaled tobacco smoke.<sup>21</sup> Cyanide may conceivably act as a protective agent in these circumstances.

#### ACKNOWLEDGEMENTS

This work was funded by the Wellcome Trust.

#### **Authors' affiliations**

**R Picton, M C Eggo, M J S Langman,** Division of Medical Sciences, Department of Medicine, University of Birmingham, Birmingham B15 2TH, UK

**G A Merrill,** Department of Clinical Investigation, Brooke Army Medical Center, Ft Sam Houston, TX 78234-6200, USA

 ${\bf S}$  Singh, Good Hope Hospital, Sutton Coldfield, Birmingham B75 7RR, UK

The opinions or assertions contained herein are the private views of the authors and are not to be construed as opinions of the Department of Defense or the Department of the Army.

#### REFERENCES

- MacFarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 1992:72:57–64.
- 2 Khan AA, Schuler MM, Prior MG, et al. Effects of hydrogen sulfide exposure on lung mitochondrial respiratory chain enzymes in rats. *Toxicol Appl Pharmacol* 1990;103:482–90.
- 3 Moore JWE, Babidge W, Millard S, et al. Effect of sulphide on short chain acyl-CoA metabolism in rat colonocytes. Gut 1997;41:77–81.

- 4 Roediger WEW. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83:424–9.
- 5 Pitcher MCL, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000;46:64–72.
- 6 **Roediger WEW**. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? *Lancet* 1980;**2**:712–15.
- 7 Weisiger RA, Pinkus LM, Jakoby WB. Thiol S-methyltransferase: suggested role in detoxication of intestinal hydrogen sulfide. *Biochem Pharmacol* 1980:29:2885–7.
- 8 Huxtable RJ. Biochemistry of sulphur. New York: Plenum, 1986:124-9.
- 9 Pacifici GM, Romiti P, Santerini S, et al. S-methyltransferases in human intestine: differential distribution of the microsomal thiol methyltransferase and cytosolic thiopurine methyltransferase along the human bowel. Xenobiotica 1993;23:671–9.
- Weinshilboum RM, Sladek S, Klumpp S. Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties. *Clin Chim Acta* 1979;97:59–71.
- Aminlari M, Gilanpour H. Comparative studies on the distribution of rhodanese in different tissues of domestic animals. *Comp Biochem Physiol-B: Comp Biochem* 1991;99:673–7.
- 12 Sorbo BH. Thiosulfate sulfurtransferase and mercaptopyruvate sulfurtransferase. In: Greenberg DM, ed. Metabolic pathways. Academic Press: New York 1975; 7:433–56.
- 13 Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. *Clin Chim Acta* 1978;85:323–33.
- 14 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54.
- 15 Merrill GA, Butler M, Horowitz PM. Limited tryptic digestion near the amino terminus of bovine liver rhodanese produces active electrophoretic variants with altered refolding. J Biol Chem 1993; 268:15611–20.
- Whitehead EP. Co-operativity and the methods of plotting binding and steady-state kinetic data. *Biochem J* 1978;171:501-4.
   Weiterer PA. Jackbu W/P. Third entry threastartic form set liver. Asch.
- 17 Weisiger RA, Jakoby WB. Thiol smethyltransferase from rat liver. Arch Biochem Biophys 1979;196:631–7.
- 18 Levitt MD, Furne JK, Springfield J, et al. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest 1999;104:1107–14.
- 19 Roediger WEW, Babidge WJ. Thiol methyltransferase activity in inflammatory bowel disease. Gut 2000;47:206–10.
- 20 Nagahara N, Okazaki T, Nishino T. Cytosolic mercaptopyruvate sulfurtransferase is evolutionarily related to mitochondrial rhodanese. J Biol Chem 1995;270:16230–5.
- 21 Wilson J, Matthews DM. Metabolic inter-relationships between cyanide, thiocyanate and vitamin B12 in smokers and non-smokers. *Clin Sci* 1966;31:1–7.